PBM Final Rule Puts Employers in Control

Experts say the rule gives sponsors the tools to drive down prescription drug costs for their plans.

The Department of Labor on October 29 issued its long-awaited final rule requiring pharmacy benefit managers to disclosure detailed information on fees, manufacturer rebates and other direct and indirect compensation the PBMs get to fiduciaries of large, employer-sponsored, self-insured group health plans covered by the Employee Retirement Income Security Act.

While hailing the rule as providing visibility into historically opaque, widely scrutinized PBM pricing practices, industry experts emphasize that it puts the pressure on sponsors to use the information to drive down prescription drug costs for their participants.

Get more!  Sign up for PLANSPONSOR newsletters.

“When we unleash all of this pricing, it’s ‘game on’ for employers to drive down the cost of care,” said Cynthia Fisher, founder and chairman of PatientRightsAdvocate, a nonprofit group that promotes healthcare transparency, during an industry-reaction panel organized by the DOL immediately following its announcement of the rule.

Background

The DOL’s “Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure,” directs PBM service providers, and any affiliated brokers or consultants, to provide ERISA group health plan fiduciaries with detailed compensation disclosures under ERISA Section 408(b)(2).

The disclosures include an initial disclosure, before the PBM enters into, renews or extends a contract with a plan, as well as at least semiannual disclosure that show the actual compensation received by the PBM and its affiliates. The rule applies to plan years beginning on or after July 1, 2027.

The DOL issued 408(b)(2) disclosure regulations in 2012, requiring covered service providers to give plan fiduciaries specified information. The Consolidated Appropriations Act of 2026 clarified that the regulations apply to PBMs. The CAA 2026 goes further for plan years beginning on or after August 3, 2028, requiring PBMs to pass through 100% of rebates, fees, alternative discounts and other renumeration they receive to their ERISA plan clients.

The CAA of 2020 had already established that ERISA health plan sponsors have the fiduciary responsibilities of compliance and transparency, as do retirement plan fiduciaries.

The DOL’s final rule on PMB disclosure builds on the CAA 2026, though each regulation has distinct timing and reporting requirements.

Organizations supporting the final rule included the ERISA Industry Committee; Transparency Rising, a nonprofit coalition of self-described “transparent” pharmacy benefit managers; the National Association of Chain Drug Stores; and the National Community Pharmacists Association, a trade group for independent pharmacies.

What Employers Can Take from the Rule

Sage Fattahian, a partner at Morgan Lewis & Bockius LLP who leads the firm’s health and welfare practice, says that while the rule is a “positive change” for employers, it remains unclear what fiduciaries will do with the new data. She says it lacks a mechanism or requirement for PBMs to negotiate lower prices with their health plan clients. It is unclear if PBMs will agree to negotiate with fiduciaries, or if they would charge higher administrative fees instead, to earn the difference between what they would otherwise lose for lowering any drug prices.

Patrick Moore, CEO and co-founder of Pretekt, a software company designed to help plan sponsors comply with health plan policy, says that while he commends the DOL’s rule for providing a new level of visibility for employers, it will also take a lot of work to understand the details of what is disclosed to them.

“Business owners got into the business of running a business,” Moore says. “They didn’t get into the business of running healthcare.”

Moore says most employers do not have the capacity to conduct the kind of scrutiny that the rule allows for.

“Who has time to look at a PBM audit four times a year?” Moore asks. However, “if I had to check the box of being a prudent fiduciary, not having an audit of my PBM contract would probably [be] unreasonable.”

For those sponsors in a self-funded arrangement that have already signed contracts with PBMs for 2027, Moore recommends asking the PBMs how they plan to comply with the new rule. He also suggests sponsors start to think through how they will audit PBM disclosures, and to select the auditor.

The final rule gives group health plans a right to audit PBM disclosures “at least once a year” and full discretion to choose the auditor.

Fattahian says fiduciaries with fiscal-year plans beginning in July 2027 should be thinking about how they will incorporate the final rule into their fiduciary governance. She says they may need to hire outside experts to help analyze the data they will receive from PBMs and to help leverage it to negotiate lower prices. Fattahian warns that this is also a challenge for fiduciary committees, as they will incur costs to hire the service providers that are intended to help them drive down costs.

During the DOL reaction panel, Steve Ditto, a consultant and project panel lead at Nautilus Health Institute, recommended sponsors review their PBM contracts, calling the documents the “control point.”

“You need to know what’s in it, you need to know how it compares to the rule, how it compares to CAA 2026, and you have to demand from your vendors—the PBM in this case—that they meet those [requirements].”

In addition to asking for a disclosure, Ditto said sponsors need to ask for the ability to terminate their contracts for cause.

Additional Considerations

John Leardi, a founding member and health attorney at Buttaci, Leardi & Werner who represents independent pharmacies, says the rule is not intended to be the “ultimate remediation” for everything the industry may perceive as wrong with how PBMs conduct business.

Leardi says that the most important takeaway for sponsors from the new rule is to pay close attention to the details in their vendor agreements and in the role. He says he anticipates that not every PBM is going to provide disclosures and data identically.

“Different plans will have different data, and they’ll come to different conclusions,” Leardi says. “And maybe through that, we’ll have a little disruption in the marketplace.”

Moore says that plan advisers also need to learn the rule and what it requires. Because advisers are likely to have no conflicts of interest with PBMs, and they have established trust with their clients, they can make a difference in helping sponsors act on the rule.

“It’s a perfect opportunity for a 401(k) adviser to see how healthcare is destroying their clients from cash flow,” Moore says.

«